Publication | Closed Access

In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells

Tyrosine Kinase InhibitorHealth SciencesMedicineReceptor Tyrosine KinaseHerbimycin AVivo Antitumor ActivityImmune Checkpoint InhibitorAnti-cancer AgentImmunotherapyPharmacologyRadiation OncologyTumor BiologyDrug DiscoveryDrug Resistance